Journal of the American Society of Hypertension
Volume 2, Issue 5 , Pages 318-325, September 2008

Oxytocin revisited: It is also a cardiovascular hormone

  • Jolanta Gutkowska, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author: Jolanta Gutkowska, PhD, Laboratory of Cardiovascular Biochemistry, Research Centre, CHUM—Hôtel-Dieu, 3850 St. Urbain Street, Masson Pavilion, Montreal, Quebec, Canada H2W 1T7. Tel: 514-890-8000 (ext. 2731); fax: 514-412-7204
  • ,
  • Marek Jankowski, PhD

Laboratory of Cardiovascular Biochemistry, Centre hospitalier de l'Université de Montréal (CHUM)—Hôtel-Dieu and Department of Medicine, Université of Montréal, Montreal, Quebec, Canada

Received 14 February 2008; accepted 17 April 2008. published online 24 June 2008.

Abstract 

Oxytocin (OT), traditionally associated with reproductive functions, was revisited recently, which revealed several new functions of the hormone in cardiovascular regulation. To support this contention, we have demonstrated the presence and synthesis of OT receptors in all heart compartments and the vasculature. The functionality of these receptors has been established by the ability of OT to induce atrial natriuretic peptide and nitric oxide (NO) release from the perfused heart and atrial slices. OT's cardiovascular actions include natriuresis, blood pressure reduction, negative inotropic and chronotropic effects, parasympathetic neuromodulation, as well as vasodilatation triggered by the NO pathway that is also involved in endothelial cell growth and anti-inflammatory activity. In addition, we have reported the abundance of the OT system in the early developing heart and OT's capacity to generate cardiomyocytes from mouse embryonic stem cells. The most potent inducer of cardiac differentiation, OT-Gly-Lys-Arg, is an extended form of OT that is abundantly expressed in the fetal heart. Therefore, in pathological conditions, OT plays an anti-inflammatory and cardioprotective role, improving vascular and metabolic functions; it has potential for therapeutic use.

Keywords: Nitric oxide, natriuretic peptides, heart, cardiomyogenesis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported by the Canadian Institute of Health Research (CIHR, MOP-53217) and the Canadian Heart and Stroke Foundation (CHSF, NET Program) as Grants to Drs. Gutkowska and Jankowski. Lecture presented In Memoriam to Professor S.M. McCann at the International Symposium on Vasoactive Peptides, Ouro Preto, Brazil, February 14 to 16, 2008.

 Conflict of interest: none.

PII: S1933-1711(08)00049-1

doi:10.1016/j.jash.2008.04.004

Journal of the American Society of Hypertension
Volume 2, Issue 5 , Pages 318-325, September 2008